Biotia
Biotia is a health-tech company based in New York, NY, dedicated to fighting infectious diseases through sequencing technology and AI-powered software. They develop advanced diagnostics and pathogen surveillance tools, including platforms like GeoSeeq and BIOTIA-DX, to improve infectious disease detection, research, and public health response. Their mission is to create the world's leading microbial sequence database and provide rapid, accurate diagnostics to enhance patient outcomes and reduce healthcare costs.
Industries
Nr. of Employees
small (1-50)
Products
Clinical-grade urine NGS diagnostic assay (state-authorized LDT)
An NGS-based in vitro diagnostic urine assay that detects a curated panel of urogenital pathogens and antimicrobial resistance markers; validated in a CLIA laboratory and approved as a state LDT.
Clinical-grade pathogen analysis software (research and clinical license)
A licensed bioinformatics application that analyzes metagenomic and targeted sequencing data to identify pathogens, call variants, and detect resistance genes, and produces interactive visualizations and reports for research or clinical use.
Research influenza genomics analysis workflow
Bioinformatic tool to analyze avian influenza virus genomes from NGS data including segment typing, clade/subclade assignment, cleavage site and mutation identification for surveillance research.
Multiplex PCR panel testing (respiratory and GI)
Provision of FDA-authorized multiplex PCR panels for respiratory and gastrointestinal pathogen detection performed in the clinical laboratory using established commercial instruments.
BIOTIA-ID Urine
An advanced genomic-based diagnostic assay for symptomatic patients with recurrent or complicated urinary tract infections, immunocompromised status, and/or sepsis of unknown origin, identifying pathogens missed by urine culture.
BIOTIA-ID Urine Test Bundle (Qty. 3)
The BIOTIA-ID Urine Test Bundle provides three (3) at-home urine collection kits and laboratory analysis for patients with recurrent, complicated, or culture-negative UTIs and current symptoms.
Clinical-grade urine NGS diagnostic assay (state-authorized LDT)
An NGS-based in vitro diagnostic urine assay that detects a curated panel of urogenital pathogens and antimicrobial resistance markers; validated in a CLIA laboratory and approved as a state LDT.
Clinical-grade pathogen analysis software (research and clinical license)
A licensed bioinformatics application that analyzes metagenomic and targeted sequencing data to identify pathogens, call variants, and detect resistance genes, and produces interactive visualizations and reports for research or clinical use.
Research influenza genomics analysis workflow
Bioinformatic tool to analyze avian influenza virus genomes from NGS data including segment typing, clade/subclade assignment, cleavage site and mutation identification for surveillance research.
Multiplex PCR panel testing (respiratory and GI)
Provision of FDA-authorized multiplex PCR panels for respiratory and gastrointestinal pathogen detection performed in the clinical laboratory using established commercial instruments.
BIOTIA-ID Urine
An advanced genomic-based diagnostic assay for symptomatic patients with recurrent or complicated urinary tract infections, immunocompromised status, and/or sepsis of unknown origin, identifying pathogens missed by urine culture.
BIOTIA-ID Urine Test Bundle (Qty. 3)
The BIOTIA-ID Urine Test Bundle provides three (3) at-home urine collection kits and laboratory analysis for patients with recurrent, complicated, or culture-negative UTIs and current symptoms.
Services
Cloud platform that integrates microbial sequencing data, epidemiological metadata and environmental/satellite data with AI tools and dashboards to support collaboration, surveillance and early-warning activities.
Analysis pipelines that convert raw sequencing data into reports with species identification, assembled genomes, lineage assignments, AMR gene detection, and visualizations; available for research and clinical workflows.
Operational support to establish local sequencing- and surveillance-capable 'watchtower' sites in underserved regions, including equipment, workflows and training to generate local genomic data streams.
Provision of NGS-based clinical testing for detection of urogenital and other infection-causing pathogens from clinical specimens in a CLIA/CLEP-certified laboratory, including report delivery to clinicians and patient portals.
RUO NGS assays and specialized analyses for research applications (e.g., joint fluid sequencing, influenza analysis, SARS-CoV-2 variant profiling), delivered with publication-grade outputs.
Cloud platform that integrates microbial sequencing data, epidemiological metadata and environmental/satellite data with AI tools and dashboards to support collaboration, surveillance and early-warning activities.
Analysis pipelines that convert raw sequencing data into reports with species identification, assembled genomes, lineage assignments, AMR gene detection, and visualizations; available for research and clinical workflows.
Operational support to establish local sequencing- and surveillance-capable 'watchtower' sites in underserved regions, including equipment, workflows and training to generate local genomic data streams.
Provision of NGS-based clinical testing for detection of urogenital and other infection-causing pathogens from clinical specimens in a CLIA/CLEP-certified laboratory, including report delivery to clinicians and patient portals.
RUO NGS assays and specialized analyses for research applications (e.g., joint fluid sequencing, influenza analysis, SARS-CoV-2 variant profiling), delivered with publication-grade outputs.
Expertise Areas
- Clinical metagenomic diagnostics
- Pathogen genomics and biosurveillance
- Bioinformatics and AI for antimicrobial resistance
- NGS assay development and validation
Key Technologies
- Next-generation sequencing (short-read)
- Long-read sequencing (ONT)
- Hybrid-capture sequencing
- Amplicon-based sequencing
News & Updates
Biotia's tool BIOTIA-DX Resistance achieved the highest prediction accuracy in the 2025 CAMDA Antimicrobial Resistance Challenge.
A joint development agreement with Mayo Clinic to enhance infectious disease diagnostics using Biotia’s platform.
Biotia received NY State Department of Health approval for its BIOTIA-ID Urine NGS Assay, the first AI-powered genomic urine test approved in NY.
A pre-print discussing the development of an early warning system for pandemics using environmental testing and genomics.
An ID Week 2023 poster on improving UTI diagnostics with genomic methods.
A study on detecting pathogens in joint infections through blood-based microbial cfDNA sequencing.
Biotia's tool BIOTIA-DX Resistance achieved the highest prediction accuracy in the 2025 CAMDA Antimicrobial Resistance Challenge.
A joint development agreement with Mayo Clinic to enhance infectious disease diagnostics using Biotia’s platform.
Biotia received NY State Department of Health approval for its BIOTIA-ID Urine NGS Assay, the first AI-powered genomic urine test approved in NY.
A pre-print discussing the development of an early warning system for pandemics using environmental testing and genomics.
An ID Week 2023 poster on improving UTI diagnostics with genomic methods.
A study on detecting pathogens in joint infections through blood-based microbial cfDNA sequencing.